Analysts have been eager to weigh in on the Healthcare sector with new ratings on VistaGen Therapeutics (VTGN), Beyondspring (BYSI) and Agenus (AGEN).
VistaGen Therapeutics (VTGN)
In a report released yesterday, Tim Lugo from William Blair maintained a Hold rating on VistaGen Therapeutics. The company’s shares closed last Monday at $0.69.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 10.4% and a 44.1% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VistaGen Therapeutics with a $1.00 average price target.
See today’s analyst top recommended stocks >>
Beyondspring (BYSI)
In a report released yesterday, Andy Hsieh from William Blair reiterated a Buy rating on Beyondspring. The company’s shares closed last Monday at $17.49.
According to TipRanks.com, Hsieh is a 5-star analyst with an average return of 24.3% and a 75.0% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Seattle Genetics, and ImmunoGen.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beyondspring with a $33.33 average price target, an 88.7% upside from current levels. In a report issued on February 7, Jefferies also initiated coverage with a Buy rating on the stock with a $25.00 price target.
Agenus (AGEN)
William Blair analyst Matt Phipps maintained a Buy rating on Agenus today. The company’s shares closed last Monday at $3.51.
According to TipRanks.com, Phipps has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.9% and a 35.2% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Autolus Therapeutics, and Portola Pharma.
Agenus has an analyst consensus of Moderate Buy, with a price target consensus of $6.00, representing a 56.7% upside. In a report issued on February 18, B.Riley FBR also reiterated a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
